Global Plant-based Virus-Like Particles (VLP) Technology Market By Type (Non-enveloped Virus-Like Particles, Enveloped Virus-Like Particles, Chimeric Virus-Like Particles); By Plant Type (Nicotiana Benthamiana (tobacco), Medicago Rativa (alfalfa), Arabidopsis thaliana (A. thaliana), Potato, Oryza sativa (Rice), Lettuce); By Process (Stable transformation system, Transient expression system); By Application (Human papillomavirus (HPV), Hepatitis B, Malaria, Norwalk Virus, HIV, Ebola Virus, SARS-CoV-2 Virus, Respiratory Syncytial Virus (RSV), Influenza Virus, Others); By End Users (Research Organizations, Biotechnology Companies, Others); By Region (Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031
Industry Trends
The world of medical science and the healthcare sector has suddenly become more cautious about newer threats, especially post coronavirus pandemic. In order to keep any sort of potential threat at bay, newer studies and research is being conducted on various things, including plant-based virus-like particles. Virus-like particles (VLPs) happen to be self-assembled structures that are created from viral antigens that have capabilities of mimicking the native architecture of viruses though the viral genome is absent. These virus-like particles are rapidly gaining popularity as a premier vaccine platform courtesy of their advantages in terms of efficacy, safety, immunogenicity, and production. Meanwhile, many vaccines that have been based on the VLP are being granted license over their use in the humans and have achieved tremendous clinical and economic success.
One of the biggest advantages of using plant expression systems is their unique posttranslational modifications, cheaper, needs less production time and ability of being scalable. Latest achievements in terms of VLPs and their chimeric derivatives in the plant systems along with their immunogenicity in non-human models are being promoted. Also the fact that the results of human clinical trials that demonstrate not just efficacy but also the efficacy of plant-derived VLPs are helping the global plant-based virus-like particles (VLP) technology market take smaller but concrete steps of the path of progress.
The recent coronavirus pandemic proved to be game-changer for the global plant-based virus-like particles (VLP) technology market. World is leaving no stone unturned to prevent such catastrophic situation in future and this is why heavy investment are being made in this market.
In terms of revenue, the global plant-based virus-like particles (VLP) technology market is projected to grow at a CAGR of 27.8% over the forecast period (2023 – 2031). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Plant-based Virus-Like Particles (VLP) Technology Market Revenue & Forecast, (US$ Million), 2023 – 2031
Plant Type Outlook
Based on the plant type outlook, the global plant-based virus-like particles (VLP) technology market has been bifurcated into nicotiana benthamiana (tobacco), medicago rativa (alfalfa), arabidopsis thaliana (A. thaliana), potato, oryza sativa (Rice), and lettuce. While tobacco and potato were among first few plants used for this purpose. The main reason that works for these plants is that they have possess tremendous similarity with insect cells in terms of native NV particles. Though other plants are being extensively researched and this will help the market in coming few years.
Region Outlook
On the basis of the region, North America is taking giants steps on the path of development and hence making massive money for the global plant-based virus-like particles (VLP) technology market in the year 2021. It can be confidently stated that the country of the United States has the best healthcare sector on this planet, followed by Canada that is home to couple of best pharmaceutical companies. The United States was in the list of nations that suffered heavily during the COVID-19 pandemic. Rampant research activities in the field of medical science in the region is the reason behind the success of this market here.
Competitive Landscape
The report provides both, qualitative and quantitative research of global plant-based virus-like particles (VLP) technology market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the key players operating in the global plant-based virus-like particles (VLP) technology market are:
- Creative Biolabs
- Creative Biostructure
- Icon Genetics GmbH
- Leaf Expression Systems
- Medicago Inc
- Wuhan Healthgen Biotechnology Corp
- Other Market Participants
Global Plant-based Virus-Like Particles (VLP) Technology Market:
By Type
- Non-enveloped Virus-Like Particles
- Enveloped Virus-Like Particles
- Chimeric Virus-Like Particles
By Plant Type
- Nicotiana benthamiana (tobacco)
- Medicago rativa (alfalfa)
- Arabidopsis thaliana (A. thaliana)
- Potato
- Oryza sativa (Rice)
- Lettuce
By Process
- Stable transformation system
- Transient expression system
By Application
- Human papillomavirus (HPV)
- Hepatitis B
- Malaria
- Norwalk Virus
- HIV
- Ebola Virus
- SARS-CoV-2 Virus
- Respiratory Syncytial Virus (RSV)
- Influenza Virus
- Others
By End Users
- Research Organizations
- Biotechnology Companies
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Forecast
Years: 2023 - 2031
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Plant-based Virus-Like Particles (VLP)
Technology Market
6. Market Synopsis:
Plant-based Virus-Like Particles (VLP) Technology Market
7. Plant-based Virus-Like Particles (VLP) Technology Market
Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Plant-based Virus-Like Particles (VLP) Technology
Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Plant-based
Virus-Like Particles (VLP) Technology Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Plant-based Virus-Like Particles (VLP)
Technology Market
8. Global Plant-based Virus-Like Particles (VLP) Technology
Market Analysis and Forecasts, 2023 - 2031
8.1. Overview
8.1.1. Global
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
8.2. Global Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Non-enveloped
Virus-Like Particles
8.2.1.1. Definition
8.2.1.2. Market
Forecast, 2023 - 2031
8.2.1.3. Compound
Annual Growth Rate (CAGR)
8.2.1.4. Regional
Bifurcation
8.2.1.4.1. North
America
8.2.1.4.1.1. Market
Forecast, 2023 - 2031
8.2.1.4.2. Europe
8.2.1.4.2.1. Market
Forecast, 2023 - 2031
8.2.1.4.3. Asia
Pacific
8.2.1.4.3.1. Market
Forecast, 2023 - 2031
8.2.1.4.4. Middle
East and Africa
8.2.1.4.4.1. Market
Forecast, 2023 - 2031
8.2.1.4.5. Latin
America
8.2.1.4.5.1. Market
Forecast, 2023 - 2031
8.2.2. Enveloped
Virus-Like Particles
8.2.2.1. Definition
8.2.2.2. Market
Forecast, 2023 - 2031
8.2.2.3. Compound
Annual Growth Rate (CAGR)
8.2.2.4. Regional
Bifurcation
8.2.2.4.1. North
America
8.2.2.4.1.1. Market
Forecast, 2023 - 2031
8.2.2.4.2. Europe
8.2.2.4.2.1. Market
Forecast, 2023 - 2031
8.2.2.4.3. Asia
Pacific
8.2.2.4.3.1. Market
Forecast, 2023 - 2031
8.2.2.4.4. Middle
East and Africa
8.2.2.4.4.1. Market
Forecast, 2023 - 2031
8.2.2.4.5. Latin
America
8.2.2.4.5.1. Market
Forecast, 2023 - 2031
8.2.3. Chimeric
Virus-Like Particles
8.2.3.1. Definition
8.2.3.2. Market
Forecast, 2023 - 2031
8.2.3.3. Compound
Annual Growth Rate (CAGR)
8.2.3.4. Regional
Bifurcation
8.2.3.4.1. North
America
8.2.3.4.1.1. Market
Forecast, 2023 - 2031
8.2.3.4.2. Europe
8.2.3.4.2.1. Market
Forecast, 2023 - 2031
8.2.3.4.3. Asia
Pacific
8.2.3.4.3.1. Market
Forecast, 2023 - 2031
8.2.3.4.4. Middle
East and Africa
8.2.3.4.4.1. Market
Forecast, 2023 - 2031
8.2.3.4.5. Latin
America
8.2.3.4.5.1. Market
Forecast, 2023 - 2031
8.3. Key Segment for Channeling Investments
8.3.1. By Type
9. Global Plant-based Virus-Like Particles (VLP) Technology
Market Analysis and Forecasts, 2023 - 2031
9.1. Overview
9.2. Global Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Plant Type
9.2.1. Nicotiana
benthamiana (tobacco)
9.2.1.1. Definition
9.2.1.2. Market
Forecast, 2023 - 2031
9.2.1.3. Compound
Annual Growth Rate (CAGR)
9.2.1.4. Regional
Bifurcation
9.2.1.4.1. North
America
9.2.1.4.1.1. Market
Forecast, 2023 - 2031
9.2.1.4.2. Europe
9.2.1.4.2.1. Market
Forecast, 2023 - 2031
9.2.1.4.3. Asia
Pacific
9.2.1.4.3.1. Market
Forecast, 2023 - 2031
9.2.1.4.4. Middle
East and Africa
9.2.1.4.4.1. Market
Forecast, 2023 - 2031
9.2.1.4.5. Latin
America
9.2.1.4.5.1. Market
Forecast, 2023 - 2031
9.2.2. Medicago
rativa (alfalfa)
9.2.2.1. Definition
9.2.2.2. Market
Forecast, 2023 - 2031
9.2.2.3. Compound
Annual Growth Rate (CAGR)
9.2.2.4. Regional
Bifurcation
9.2.2.4.1. North
America
9.2.2.4.1.1. Market
Forecast, 2023 - 2031
9.2.2.4.2. Europe
9.2.2.4.2.1. Market
Forecast, 2023 - 2031
9.2.2.4.3. Asia
Pacific
9.2.2.4.3.1. Market
Forecast, 2023 - 2031
9.2.2.4.4. Middle
East and Africa
9.2.2.4.4.1. Market
Forecast, 2023 - 2031
9.2.2.4.5. Latin
America
9.2.2.4.5.1. Market
Forecast, 2023 - 2031
9.2.3. Arabidopsis
thaliana (A. thaliana)
9.2.3.1. Definition
9.2.3.2. Market
Forecast, 2023 - 2031
9.2.3.3. Compound
Annual Growth Rate (CAGR)
9.2.3.4. Regional
Bifurcation
9.2.3.4.1. North
America
9.2.3.4.1.1. Market
Forecast, 2023 - 2031
9.2.3.4.2. Europe
9.2.3.4.2.1. Market
Forecast, 2023 - 2031
9.2.3.4.3. Asia
Pacific
9.2.3.4.3.1. Market
Forecast, 2023 - 2031
9.2.3.4.4. Middle
East and Africa
9.2.3.4.4.1. Market
Forecast, 2023 - 2031
9.2.3.4.5. Latin
America
9.2.3.4.5.1. Market
Forecast, 2023 - 2031
9.2.4. Potato
9.2.4.1. Definition
9.2.4.2. Market
Forecast, 2023 - 2031
9.2.4.3. Compound
Annual Growth Rate (CAGR)
9.2.4.4. Regional
Bifurcation
9.2.4.4.1. North
America
9.2.4.4.1.1. Market
Forecast, 2023 - 2031
9.2.4.4.2. Europe
9.2.4.4.2.1. Market
Forecast, 2023 - 2031
9.2.4.4.3. Asia
Pacific
9.2.4.4.3.1. Market
Forecast, 2023 - 2031
9.2.4.4.4. Middle
East and Africa
9.2.4.4.4.1. Market
Forecast, 2023 - 2031
9.2.4.4.5. Latin
America
9.2.4.4.5.1. Market
Forecast, 2023 - 2031
9.2.5. Oryza
sativa (Rice)
9.2.5.1. Definition
9.2.5.2. Market
Forecast, 2023 - 2031
9.2.5.3. Compound
Annual Growth Rate (CAGR)
9.2.5.4. Regional
Bifurcation
9.2.5.4.1. North
America
9.2.5.4.1.1. Market
Forecast, 2023 - 2031
9.2.5.4.2. Europe
9.2.5.4.2.1. Market
Forecast, 2023 - 2031
9.2.5.4.3. Asia
Pacific
9.2.5.4.3.1. Market
Forecast, 2023 - 2031
9.2.5.4.4. Middle
East and Africa
9.2.5.4.4.1. Market
Forecast, 2023 - 2031
9.2.5.4.5. Latin
America
9.2.5.4.5.1. Market
Forecast, 2023 - 2031
9.2.6. Lettuce
9.2.6.1. Definition
9.2.6.2. Market
Forecast, 2023 - 2031
9.2.6.3. Compound
Annual Growth Rate (CAGR)
9.2.6.4. Regional
Bifurcation
9.2.6.4.1. North
America
9.2.6.4.1.1. Market
Forecast, 2023 - 2031
9.2.6.4.2. Europe
9.2.6.4.2.1. Market
Forecast, 2023 - 2031
9.2.6.4.3. Asia
Pacific
9.2.6.4.3.1. Market
Forecast, 2023 - 2031
9.2.6.4.4. Middle
East and Africa
9.2.6.4.4.1. Market
Forecast, 2023 - 2031
9.2.6.4.5. Latin
America
9.2.6.4.5.1. Market
Forecast, 2023 - 2031
9.3. Key Segment for Channeling Investments
9.3.1. By Plant
Type
10. Global Plant-based Virus-Like Particles (VLP) Technology
Market Analysis and Forecasts, 2023 - 2031
10.1. Overview
10.2. Global Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Process
10.2.1. Stable
transformation system
10.2.1.1. Definition
10.2.1.2. Market
Forecast, 2023 - 2031
10.2.1.3. Compound
Annual Growth Rate (CAGR)
10.2.1.4. Regional
Bifurcation
10.2.1.4.1. North
America
10.2.1.4.1.1. Market
Forecast, 2023 - 2031
10.2.1.4.2. Europe
10.2.1.4.2.1. Market
Forecast, 2023 - 2031
10.2.1.4.3. Asia
Pacific
10.2.1.4.3.1. Market
Forecast, 2023 - 2031
10.2.1.4.4. Middle
East and Africa
10.2.1.4.4.1. Market
Forecast, 2023 - 2031
10.2.1.4.5. Latin
America
10.2.1.4.5.1. Market
Forecast, 2023 - 2031
10.2.1.4.6. Latin
America
10.2.1.4.6.1. Market
Forecast, 2023 - 2031
10.2.2. Transient
expression system
10.2.2.1. Definition
10.2.2.2. Market
Forecast, 2023 - 2031
10.2.2.3. Compound
Annual Growth Rate (CAGR)
10.2.2.4. Regional
Bifurcation
10.2.2.4.1. North
America
10.2.2.4.1.1. Market
Forecast, 2023 - 2031
10.2.2.4.2. Europe
10.2.2.4.2.1. Market
Forecast, 2023 - 2031
10.2.2.4.3. Asia
Pacific
10.2.2.4.3.1. Market
Forecast, 2023 - 2031
10.2.2.4.4. Middle
East and Africa
10.2.2.4.4.1. Market
Forecast, 2023 - 2031
10.2.2.4.5. Latin
America
10.2.2.4.5.1. Market
Forecast, 2023 - 2031
10.2.2.4.6. Latin
America
10.2.2.4.6.1. Market
Forecast, 2023 - 2031
10.3. Key Segment for Channeling Investments
10.3.1. By
Process
11. Global Plant-based Virus-Like Particles (VLP) Technology
Market Analysis and Forecasts, 2023 - 2031
11.1. Overview
11.2. Global Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Application
11.2.1. Human
papillomavirus (HPV)
11.2.1.1. Definition
11.2.1.2. Market
Forecast, 2023 - 2031
11.2.1.3. Compound
Annual Growth Rate (CAGR)
11.2.1.4. Regional
Bifurcation
11.2.1.4.1. North
America
11.2.1.4.1.1. Market
Forecast, 2023 - 2031
11.2.1.4.2. Europe
11.2.1.4.2.1. Market
Forecast, 2023 - 2031
11.2.1.4.3. Asia
Pacific
11.2.1.4.3.1. Market
Forecast, 2023 - 2031
11.2.1.4.4. Middle
East and Africa
11.2.1.4.4.1. Market
Forecast, 2023 - 2031
11.2.1.4.5. Latin
America
11.2.1.4.5.1. Market
Forecast, 2023 - 2031
11.2.2. Hepatitis
B
11.2.2.1. Definition
11.2.2.2. Market
Forecast, 2023 - 2031
11.2.2.3. Compound
Annual Growth Rate (CAGR)
11.2.2.4. Regional
Bifurcation
11.2.2.4.1. North
America
11.2.2.4.1.1. Market
Forecast, 2023 - 2031
11.2.2.4.2. Europe
11.2.2.4.2.1. Market
Forecast, 2023 - 2031
11.2.2.4.3. Asia
Pacific
11.2.2.4.3.1. Market
Forecast, 2023 - 2031
11.2.2.4.4. Middle
East and Africa
11.2.2.4.4.1. Market
Forecast, 2023 - 2031
11.2.2.4.5. Latin
America
11.2.2.4.5.1. Market
Forecast, 2023 - 2031
11.2.3. Malaria
11.2.3.1. Definition
11.2.3.2. Market
Forecast, 2023 - 2031
11.2.3.3. Compound
Annual Growth Rate (CAGR)
11.2.3.4. Regional
Bifurcation
11.2.3.4.1. North
America
11.2.3.4.1.1. Market
Forecast, 2023 - 2031
11.2.3.4.2. Europe
11.2.3.4.2.1. Market
Forecast, 2023 - 2031
11.2.3.4.3. Asia
Pacific
11.2.3.4.3.1. Market
Forecast, 2023 - 2031
11.2.3.4.4. Middle
East and Africa
11.2.3.4.4.1. Market
Forecast, 2023 - 2031
11.2.3.4.5. Latin
America
11.2.3.4.5.1. Market
Forecast, 2023 - 2031
11.2.4. Norwalk
Virus
11.2.4.1. Definition
11.2.4.2. Market
Forecast, 2023 - 2031
11.2.4.3. Compound
Annual Growth Rate (CAGR)
11.2.4.4. Regional
Bifurcation
11.2.4.4.1. North
America
11.2.4.4.1.1. Market
Forecast, 2023 - 2031
11.2.4.4.2. Europe
11.2.4.4.2.1. Market
Forecast, 2023 - 2031
11.2.4.4.3. Asia
Pacific
11.2.4.4.3.1. Market
Forecast, 2023 - 2031
11.2.4.4.4. Middle
East and Africa
11.2.4.4.4.1. Market
Forecast, 2023 - 2031
11.2.4.4.5. Latin
America
11.2.4.4.5.1. Market
Forecast, 2023 - 2031
11.2.5. HIV
11.2.5.1. Definition
11.2.5.2. Market
Forecast, 2023 - 2031
11.2.5.3. Compound
Annual Growth Rate (CAGR)
11.2.5.4. Regional
Bifurcation
11.2.5.4.1. North
America
11.2.5.4.1.1. Market
Forecast, 2023 - 2031
11.2.5.4.2. Europe
11.2.5.4.2.1. Market
Forecast, 2023 - 2031
11.2.5.4.3. Asia
Pacific
11.2.5.4.3.1. Market
Forecast, 2023 - 2031
11.2.5.4.4. Middle
East and Africa
11.2.5.4.4.1. Market
Forecast, 2023 - 2031
11.2.5.4.5. Latin
America
11.2.5.4.5.1. Market
Forecast, 2023 - 2031
11.2.6. Ebola
Virus
11.2.6.1. Definition
11.2.6.2. Market
Forecast, 2023 - 2031
11.2.6.3. Compound
Annual Growth Rate (CAGR)
11.2.6.4. Regional
Bifurcation
11.2.6.4.1. North
America
11.2.6.4.1.1. Market
Forecast, 2023 - 2031
11.2.6.4.2. Europe
11.2.6.4.2.1. Market
Forecast, 2023 - 2031
11.2.6.4.3. Asia
Pacific
11.2.6.4.3.1. Market
Forecast, 2023 - 2031
11.2.6.4.4. Middle
East and Africa
11.2.6.4.4.1. Market
Forecast, 2023 - 2031
11.2.6.4.5. Latin
America
11.2.6.4.5.1. Market
Forecast, 2023 - 2031
11.2.7. SARS-CoV-2
Virus
11.2.7.1. Definition
11.2.7.2. Market
Forecast, 2023 - 2031
11.2.7.3. Compound
Annual Growth Rate (CAGR)
11.2.7.4. Regional
Bifurcation
11.2.7.4.1. North
America
11.2.7.4.1.1. Market
Forecast, 2023 - 2031
11.2.7.4.2. Europe
11.2.7.4.2.1. Market
Forecast, 2023 - 2031
11.2.7.4.3. Asia
Pacific
11.2.7.4.3.1. Market
Forecast, 2023 - 2031
11.2.7.4.4. Middle
East and Africa
11.2.7.4.4.1. Market
Forecast, 2023 - 2031
11.2.7.4.5. Latin
America
11.2.7.4.5.1. Market
Forecast, 2023 - 2031
11.2.8. Respiratory
Syncytial Virus (RSV)
11.2.8.1. Definition
11.2.8.2. Market
Forecast, 2023 - 2031
11.2.8.3. Compound
Annual Growth Rate (CAGR)
11.2.8.4. Regional
Bifurcation
11.2.8.4.1. North
America
11.2.8.4.1.1. Market
Forecast, 2023 - 2031
11.2.8.4.2. Europe
11.2.8.4.2.1. Market
Forecast, 2023 - 2031
11.2.8.4.3. Asia
Pacific
11.2.8.4.3.1. Market
Forecast, 2023 - 2031
11.2.8.4.4. Middle
East and Africa
11.2.8.4.4.1. Market
Forecast, 2023 - 2031
11.2.8.4.5. Latin
America
11.2.8.4.5.1. Market
Forecast, 2023 - 2031
11.2.9. Influenza
Virus
11.2.9.1. Definition
11.2.9.2. Market
Forecast, 2023 - 2031
11.2.9.3. Compound
Annual Growth Rate (CAGR)
11.2.9.4. Regional
Bifurcation
11.2.9.4.1. North
America
11.2.9.4.1.1. Market
Forecast, 2023 - 2031
11.2.9.4.2. Europe
11.2.9.4.2.1. Market
Forecast, 2023 - 2031
11.2.9.4.3. Asia
Pacific
11.2.9.4.3.1. Market
Forecast, 2023 - 2031
11.2.9.4.4. Middle
East and Africa
11.2.9.4.4.1. Market
Forecast, 2023 - 2031
11.2.9.4.5. Latin
America
11.2.9.4.5.1. Market
Forecast, 2023 - 2031
11.2.10. Others
11.2.10.1. Definition
11.2.10.2. Market
Forecast, 2023 - 2031
11.2.10.3. Compound
Annual Growth Rate (CAGR)
11.2.10.4. Regional
Bifurcation
11.2.10.4.1. North
America
11.2.10.4.1.1. Market
Forecast, 2023 - 2031
11.2.10.4.2. Europe
11.2.10.4.2.1. Market
Forecast, 2023 - 2031
11.2.10.4.3. Asia
Pacific
11.2.10.4.3.1. Market
Forecast, 2023 - 2031
11.2.10.4.4. Middle
East and Africa
11.2.10.4.4.1. Market
Forecast, 2023 - 2031
11.2.10.4.5. Latin
America
11.2.10.4.5.1. Market
Forecast, 2023 - 2031
11.3. Key Segment for Channeling Investments
11.3.1. By
Application
12. Global Plant-based Virus-Like Particles (VLP) Technology
Market Analysis and Forecasts, 2023 - 2031
12.1. Overview
12.2. Global Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By End Users
12.2.1. Research
Organizations
12.2.1.1.
Definition
12.2.1.2.
Market Forecast, 2023 - 2031
12.2.1.3.
Compound Annual Growth Rate (CAGR)
12.2.1.4.
Regional Bifurcation
12.2.1.4.1. North
America
12.2.1.4.1.1. Market
Forecast, 2023 - 2031
12.2.1.4.2. Europe
12.2.1.4.2.1. Market
Forecast, 2023 - 2031
12.2.1.4.3. Asia
Pacific
12.2.1.4.3.1. Market
Forecast, 2023 - 2031
12.2.1.4.4. Middle
East and Africa
12.2.1.4.4.1. Market
Forecast, 2023 - 2031
12.2.1.4.5. Latin
America
12.2.1.4.5.1. Market
Forecast, 2023 - 2031
12.2.2. Biotechnology
Companies
12.2.2.1.
Definition
12.2.2.2.
Market Forecast, 2023 - 2031
12.2.2.3.
Compound Annual Growth Rate (CAGR)
12.2.2.4.
Regional Bifurcation
12.2.2.4.1. North
America
12.2.2.4.1.1. Market
Forecast, 2023 - 2031
12.2.2.4.2. Europe
12.2.2.4.2.1. Market
Forecast, 2023 - 2031
12.2.2.4.3. Asia
Pacific
12.2.2.4.3.1. Market
Forecast, 2023 - 2031
12.2.2.4.4. Middle
East and Africa
12.2.2.4.4.1. Market
Forecast, 2023 - 2031
12.2.2.4.5. Latin
America
12.2.2.4.5.1. Market
Forecast, 2023 - 2031
12.2.3. Others
12.2.3.1.
Definition
12.2.3.2.
Market Forecast, 2023 - 2031
12.2.3.3.
Compound Annual Growth Rate (CAGR)
12.2.3.4.
Regional Bifurcation
12.2.3.4.1. North
America
12.2.3.4.1.1. Market
Forecast, 2023 - 2031
12.2.3.4.2. Europe
12.2.3.4.2.1. Market
Forecast, 2023 - 2031
12.2.3.4.3. Asia
Pacific
12.2.3.4.3.1. Market
Forecast, 2023 - 2031
12.2.3.4.4. Middle
East and Africa
12.2.3.4.4.1. Market
Forecast, 2023 - 2031
12.2.3.4.5. Latin
America
12.2.3.4.5.1. Market
Forecast, 2023 - 2031
12.3. Key Segment for Channeling Investments
12.3.1. By End
Users
13. North America Plant-based Virus-Like Particles (VLP)
Technology Market Analysis and Forecasts, 2023 - 2031
13.1. Overview
13.1.1. North
America Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn)
13.2. North America Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Non-enveloped
Virus-Like Particles
13.2.2. Enveloped
Virus-Like Particles
13.2.3. Chimeric
Virus-Like Particles
13.3. North America Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Plant Type
13.3.1. Nicotiana
benthamiana (tobacco)
13.3.2. Medicago
rativa (alfalfa)
13.3.3. Arabidopsis
thaliana (A. thaliana)
13.3.4. Potato
13.3.5. Oryza
sativa (Rice)
13.3.6. Lettuce
13.4. North America Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Process
13.4.1. Stable
transformation system
13.4.2. Transient
expression system
13.5. North America Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1. Human
papillomavirus (HPV)
13.5.2. Hepatitis
B
13.5.3. Malaria
13.5.4. Norwalk
Virus
13.5.5. HIV
13.5.6. Ebola
Virus
13.5.7. SARS-CoV-2
Virus
13.5.8. Respiratory
Syncytial Virus (RSV)
13.5.9. Influenza
Virus
13.5.10. Others
13.6. North America Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.1. Research
Organizations
13.6.2. Biotechnology
Companies
13.6.3. Others
13.7. North America Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1. U.S
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
13.7.1.1.1. Non-enveloped
Virus-Like Particles
13.7.1.1.2. Enveloped
Virus-Like Particles
13.7.1.1.3. Chimeric
Virus-Like Particles
13.7.1.2. U.S
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
13.7.1.2.1. Nicotiana
benthamiana (tobacco)
13.7.1.2.2. Medicago
rativa (alfalfa)
13.7.1.2.3. Arabidopsis
thaliana (A. thaliana)
13.7.1.2.4. Potato
13.7.1.2.5. Oryza
sativa (Rice)
13.7.1.2.6. Lettuce
13.7.1.3. U.S
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
13.7.1.3.1. Stable
transformation system
13.7.1.3.2. Transient
expression system
13.7.1.4. U.S
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
13.7.1.4.1. Human
papillomavirus (HPV)
13.7.1.4.2. Hepatitis
B
13.7.1.4.3. Malaria
13.7.1.4.4. Norwalk
Virus
13.7.1.4.5. HIV
13.7.1.4.6. Ebola
Virus
13.7.1.4.7. SARS-CoV-2
Virus
13.7.1.4.8. Respiratory
Syncytial Virus (RSV)
13.7.1.4.9. Influenza
Virus
13.7.1.4.10. Others
13.7.1.5. U.S
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
13.7.1.5.1. Research
Organizations
13.7.1.5.2. Biotechnology
Companies
13.7.1.5.3. Others
13.7.2. Canada
13.7.2.1. Canada
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
13.7.2.1.1. Non-enveloped
Virus-Like Particles
13.7.2.1.2. Enveloped
Virus-Like Particles
13.7.2.1.3. Chimeric
Virus-Like Particles
13.7.2.2. Canada
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
13.7.2.2.1. Nicotiana
benthamiana (tobacco)
13.7.2.2.2. Medicago
rativa (alfalfa)
13.7.2.2.3. Arabidopsis
thaliana (A. thaliana)
13.7.2.2.4. Potato
13.7.2.2.5. Oryza
sativa (Rice)
13.7.2.2.6. Lettuce
13.7.2.3. Canada
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
13.7.2.3.1. Stable
transformation system
13.7.2.3.2. Transient
expression system
13.7.2.4. Canada
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
13.7.2.4.1. Human
papillomavirus (HPV)
13.7.2.4.2. Hepatitis
B
13.7.2.4.3. Malaria
13.7.2.4.4. Norwalk
Virus
13.7.2.4.5. HIV
13.7.2.4.6. Ebola
Virus
13.7.2.4.7. SARS-CoV-2
Virus
13.7.2.4.8. Respiratory
Syncytial Virus (RSV)
13.7.2.4.9. Influenza
Virus
13.7.2.4.10. Others
13.7.2.5. Canada
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
13.7.2.5.1. Research
Organizations
13.7.2.5.2. Biotechnology
Companies
13.7.2.5.3. Others
13.7.3. Mexico
13.7.3.1. Mexico
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
13.7.3.1.1. Non-enveloped
Virus-Like Particles
13.7.3.1.2. Enveloped
Virus-Like Particles
13.7.3.1.3. Chimeric
Virus-Like Particles
13.7.3.2. Mexico
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
13.7.3.2.1. Nicotiana
benthamiana (tobacco)
13.7.3.2.2. Medicago
rativa (alfalfa)
13.7.3.2.3. Arabidopsis
thaliana (A. thaliana)
13.7.3.2.4. Potato
13.7.3.2.5. Oryza
sativa (Rice)
13.7.3.2.6. Lettuce
13.7.3.3. Mexico
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
13.7.3.3.1. Stable
transformation system
13.7.3.3.2. Transient
expression system
13.7.3.4. Mexico
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
13.7.3.4.1. Human
papillomavirus (HPV)
13.7.3.4.2. Hepatitis
B
13.7.3.4.3. Malaria
13.7.3.4.4. Norwalk
Virus
13.7.3.4.5. HIV
13.7.3.4.6. Ebola
Virus
13.7.3.4.7. SARS-CoV-2
Virus
13.7.3.4.8. Respiratory
Syncytial Virus (RSV)
13.7.3.4.9. Influenza
Virus
13.7.3.4.10. Others
13.7.3.5. Mexico
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
13.7.3.5.1. Research
Organizations
13.7.3.5.2. Biotechnology
Companies
13.7.3.5.3. Others
13.7.4. Rest of
North America
13.7.4.1. Rest
of North America Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By Type
13.7.4.1.1. Non-enveloped
Virus-Like Particles
13.7.4.1.2. Enveloped
Virus-Like Particles
13.7.4.1.3. Chimeric
Virus-Like Particles
13.7.4.2. Rest
of North America Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By Plant Type
13.7.4.2.1. Nicotiana
benthamiana (tobacco)
13.7.4.2.2. Medicago
rativa (alfalfa)
13.7.4.2.3. Arabidopsis
thaliana (A. thaliana)
13.7.4.2.4. Potato
13.7.4.2.5. Oryza
sativa (Rice)
13.7.4.2.6. Lettuce
13.7.4.3. Rest
of North America Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By Process
13.7.4.3.1. Stable
transformation system
13.7.4.3.2. Transient
expression system
13.7.4.4. Rest
of North America Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By Application
13.7.4.4.1. Human
papillomavirus (HPV)
13.7.4.4.2. Hepatitis
B
13.7.4.4.3. Malaria
13.7.4.4.4. Norwalk
Virus
13.7.4.4.5. HIV
13.7.4.4.6. Ebola
Virus
13.7.4.4.7. SARS-CoV-2
Virus
13.7.4.4.8. Respiratory
Syncytial Virus (RSV)
13.7.4.4.9. Influenza
Virus
13.7.4.4.10. Others
13.7.4.5. Rest
of North America Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By End Users
13.7.4.5.1. Research
Organizations
13.7.4.5.2. Biotechnology
Companies
13.7.4.5.3. Others
13.8. Key Segment for Channeling Investments
13.8.1. By
Country
13.8.2. By Type
13.8.3. By
Plant Type
13.8.4. By
Process
13.8.5. By Application
13.8.6. By End
Users
14. Europe Plant-based Virus-Like Particles (VLP) Technology
Market Analysis and Forecasts, 2023 - 2031
14.1. Overview
14.1.1. Europe
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
14.2. Europe Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Non-enveloped
Virus-Like Particles
14.2.2. Enveloped
Virus-Like Particles
14.2.3. Chimeric
Virus-Like Particles
14.3. Europe Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Plant Type
14.3.1. Nicotiana
benthamiana (tobacco)
14.3.2. Medicago
rativa (alfalfa)
14.3.3. Arabidopsis
thaliana (A. thaliana)
14.3.4. Potato
14.3.5. Oryza
sativa (Rice)
14.3.6. Lettuce
14.4. Europe Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Process
14.4.1. Stable
transformation system
14.4.2. Transient
expression system
14.5. Europe Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Application
14.5.1. Human
papillomavirus (HPV)
14.5.2. Hepatitis
B
14.5.3. Malaria
14.5.4. Norwalk
Virus
14.5.5. HIV
14.5.6. Ebola
Virus
14.5.7. SARS-CoV-2
Virus
14.5.8. Respiratory
Syncytial Virus (RSV)
14.5.9. Influenza
Virus
14.5.10. Others
14.6. Europe Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.1. Research
Organizations
14.6.2. Biotechnology
Companies
14.6.3. Others
14.7. Europe Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Country
14.7.1. France
14.7.1.1. France
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.1.1.1. Non-enveloped
Virus-Like Particles
14.7.1.1.2. Enveloped
Virus-Like Particles
14.7.1.1.3. Chimeric
Virus-Like Particles
14.7.1.2. France
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
14.7.1.2.1. Nicotiana
benthamiana (tobacco)
14.7.1.2.2. Medicago
rativa (alfalfa)
14.7.1.2.3. Arabidopsis
thaliana (A. thaliana)
14.7.1.2.4. Potato
14.7.1.2.5. Oryza
sativa (Rice)
14.7.1.2.6. Lettuce
14.7.1.3. France
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
14.7.1.3.1. Stable
transformation system
14.7.1.3.2. Transient
expression system
14.7.1.4. France
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
14.7.1.4.1. Human
papillomavirus (HPV)
14.7.1.4.2. Hepatitis
B
14.7.1.4.3. Malaria
14.7.1.4.4. Norwalk
Virus
14.7.1.4.5. HIV
14.7.1.4.6. Ebola
Virus
14.7.1.4.7. SARS-CoV-2
Virus
14.7.1.4.8. Respiratory
Syncytial Virus (RSV)
14.7.1.4.9. Influenza
Virus
14.7.1.4.10. Others
14.7.1.5. France
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
14.7.1.5.1. Research
Organizations
14.7.1.5.2. Biotechnology
Companies
14.7.1.5.3. Others
14.7.2. The UK
14.7.2.1. The
UK Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Type
14.7.2.1.1. Non-enveloped
Virus-Like Particles
14.7.2.1.2. Enveloped
Virus-Like Particles
14.7.2.1.3. Chimeric
Virus-Like Particles
14.7.2.2. The
UK Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Plant Type
14.7.2.2.1. Nicotiana
benthamiana (tobacco)
14.7.2.2.2. Medicago
rativa (alfalfa)
14.7.2.2.3. Arabidopsis
thaliana (A. thaliana)
14.7.2.2.4. Potato
14.7.2.2.5. Oryza
sativa (Rice)
14.7.2.2.6. Lettuce
14.7.2.3. The
UK Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Process
14.7.2.3.1. Stable
transformation system
14.7.2.3.2. Transient
expression system
14.7.2.4. The
UK Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Application
14.7.2.4.1. Human
papillomavirus (HPV)
14.7.2.4.2. Hepatitis
B
14.7.2.4.3. Malaria
14.7.2.4.4. Norwalk
Virus
14.7.2.4.5. HIV
14.7.2.4.6. Ebola
Virus
14.7.2.4.7. SARS-CoV-2
Virus
14.7.2.4.8. Respiratory
Syncytial Virus (RSV)
14.7.2.4.9. Influenza
Virus
14.7.2.4.10. Others
14.7.2.5. The
UK Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By End Users
14.7.2.5.1. Research
Organizations
14.7.2.5.2. Biotechnology
Companies
14.7.2.5.3. Others
14.7.3. Spain
14.7.3.1. Spain
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.3.1.1. Non-enveloped
Virus-Like Particles
14.7.3.1.2. Enveloped
Virus-Like Particles
14.7.3.1.3. Chimeric
Virus-Like Particles
14.7.3.2. Spain
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
14.7.3.2.1. Nicotiana
benthamiana (tobacco)
14.7.3.2.2. Medicago
rativa (alfalfa)
14.7.3.2.3. Arabidopsis
thaliana (A. thaliana)
14.7.3.2.4. Potato
14.7.3.2.5. Oryza
sativa (Rice)
14.7.3.2.6. Lettuce
14.7.3.3. Spain
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
14.7.3.3.1. Stable
transformation system
14.7.3.3.2. Transient
expression system
14.7.3.4. Spain
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
14.7.3.4.1. Human
papillomavirus (HPV)
14.7.3.4.2. Hepatitis
B
14.7.3.4.3. Malaria
14.7.3.4.4. Norwalk
Virus
14.7.3.4.5. HIV
14.7.3.4.6. Ebola
Virus
14.7.3.4.7. SARS-CoV-2
Virus
14.7.3.4.8. Respiratory
Syncytial Virus (RSV)
14.7.3.4.9. Influenza
Virus
14.7.3.4.10. Others
14.7.3.5. Spain
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
14.7.3.5.1. Research
Organizations
14.7.3.5.2. Biotechnology
Companies
14.7.3.5.3. Others
14.7.4. Germany
14.7.4.1. Germany
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.4.1.1. Non-enveloped
Virus-Like Particles
14.7.4.1.2. Enveloped
Virus-Like Particles
14.7.4.1.3. Chimeric
Virus-Like Particles
14.7.4.2. Germany
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
14.7.4.2.1. Nicotiana
benthamiana (tobacco)
14.7.4.2.2. Medicago
rativa (alfalfa)
14.7.4.2.3. Arabidopsis
thaliana (A. thaliana)
14.7.4.2.4. Potato
14.7.4.2.5. Oryza
sativa (Rice)
14.7.4.2.6. Lettuce
14.7.4.3. Germany
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
14.7.4.3.1. Stable
transformation system
14.7.4.3.2. Transient
expression system
14.7.4.4. Germany
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
14.7.4.4.1. Human
papillomavirus (HPV)
14.7.4.4.2. Hepatitis
B
14.7.4.4.3. Malaria
14.7.4.4.4. Norwalk
Virus
14.7.4.4.5. HIV
14.7.4.4.6. Ebola
Virus
14.7.4.4.7. SARS-CoV-2
Virus
14.7.4.4.8. Respiratory
Syncytial Virus (RSV)
14.7.4.4.9. Influenza
Virus
14.7.4.4.10. Others
14.7.4.5. Germany
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
14.7.4.5.1. Research
Organizations
14.7.4.5.2. Biotechnology
Companies
14.7.4.5.3. Others
14.7.5. Italy
14.7.5.1. Italy
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.5.1.1. Non-enveloped
Virus-Like Particles
14.7.5.1.2. Enveloped
Virus-Like Particles
14.7.5.1.3. Chimeric
Virus-Like Particles
14.7.5.2. Italy
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
14.7.5.2.1. Nicotiana
benthamiana (tobacco)
14.7.5.2.2. Medicago
rativa (alfalfa)
14.7.5.2.3. Arabidopsis
thaliana (A. thaliana)
14.7.5.2.4. Potato
14.7.5.2.5. Oryza
sativa (Rice)
14.7.5.2.6. Lettuce
14.7.5.3. Italy
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
14.7.5.3.1. Stable
transformation system
14.7.5.3.2. Transient
expression system
14.7.5.4. Italy
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
14.7.5.4.1. Human
papillomavirus (HPV)
14.7.5.4.2. Hepatitis
B
14.7.5.4.3. Malaria
14.7.5.4.4. Norwalk
Virus
14.7.5.4.5. HIV
14.7.5.4.6. Ebola
Virus
14.7.5.4.7. SARS-CoV-2
Virus
14.7.5.4.8. Respiratory
Syncytial Virus (RSV)
14.7.5.4.9. Influenza
Virus
14.7.5.4.10. Others
14.7.5.5. Italy
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
14.7.5.5.1. Research
Organizations
14.7.5.5.2. Biotechnology
Companies
14.7.5.5.3. Others
14.7.6. Nordic
Countries
14.7.6.1. Nordic
Countries Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Type
14.7.6.1.1. Non-enveloped
Virus-Like Particles
14.7.6.1.2. Enveloped
Virus-Like Particles
14.7.6.1.3. Chimeric
Virus-Like Particles
14.7.6.2. Nordic
Countries Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Plant Type
14.7.6.2.1. Nicotiana
benthamiana (tobacco)
14.7.6.2.2. Medicago
rativa (alfalfa)
14.7.6.2.3. Arabidopsis
thaliana (A. thaliana)
14.7.6.2.4. Potato
14.7.6.2.5. Oryza
sativa (Rice)
14.7.6.2.6. Lettuce
14.7.6.3. Nordic
Countries Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Process
14.7.6.3.1. Stable
transformation system
14.7.6.3.2. Transient
expression system
14.7.6.4. Nordic
Countries Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Application
14.7.6.4.1. Human
papillomavirus (HPV)
14.7.6.4.2. Hepatitis
B
14.7.6.4.3. Malaria
14.7.6.4.4. Norwalk
Virus
14.7.6.4.5. HIV
14.7.6.4.6. Ebola
Virus
14.7.6.4.7. SARS-CoV-2
Virus
14.7.6.4.8. Respiratory
Syncytial Virus (RSV)
14.7.6.4.9. Influenza
Virus
14.7.6.4.10. Others
14.7.6.5. Nordic
Countries Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By End Users
14.7.6.5.1. Research
Organizations
14.7.6.5.2. Biotechnology
Companies
14.7.6.5.3. Others
14.7.6.6. Nordic
Countries Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux
Union
14.7.7.1. Benelux
Union Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Type
14.7.7.1.1. Non-enveloped
Virus-Like Particles
14.7.7.1.2. Enveloped
Virus-Like Particles
14.7.7.1.3. Chimeric
Virus-Like Particles
14.7.7.2. Benelux
Union Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Plant Type
14.7.7.2.1. Nicotiana
benthamiana (tobacco)
14.7.7.2.2. Medicago
rativa (alfalfa)
14.7.7.2.3. Arabidopsis
thaliana (A. thaliana)
14.7.7.2.4. Potato
14.7.7.2.5. Oryza
sativa (Rice)
14.7.7.2.6. Lettuce
14.7.7.3. Benelux
Union Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Process
14.7.7.3.1. Stable
transformation system
14.7.7.3.2. Transient
expression system
14.7.7.4. Benelux
Union Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Application
14.7.7.4.1. Human
papillomavirus (HPV)
14.7.7.4.2. Hepatitis
B
14.7.7.4.3. Malaria
14.7.7.4.4. Norwalk
Virus
14.7.7.4.5. HIV
14.7.7.4.6. Ebola
Virus
14.7.7.4.7. SARS-CoV-2
Virus
14.7.7.4.8. Respiratory
Syncytial Virus (RSV)
14.7.7.4.9. Influenza
Virus
14.7.7.4.10. Others
14.7.7.5. Benelux
Union Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By End Users
14.7.7.5.1. Research
Organizations
14.7.7.5.2. Biotechnology
Companies
14.7.7.5.3. Others
14.7.7.6. Benelux
Union Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The
Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of
Europe
14.7.8.1. Rest
of Europe Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Type
14.7.8.1.1. Non-enveloped
Virus-Like Particles
14.7.8.1.2. Enveloped
Virus-Like Particles
14.7.8.1.3. Chimeric
Virus-Like Particles
14.7.8.2. Rest
of Europe Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Plant Type
14.7.8.2.1. Nicotiana
benthamiana (tobacco)
14.7.8.2.2. Medicago
rativa (alfalfa)
14.7.8.2.3. Arabidopsis
thaliana (A. thaliana)
14.7.8.2.4. Potato
14.7.8.2.5. Oryza
sativa (Rice)
14.7.8.2.6. Lettuce
14.7.8.3. Rest
of Europe Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Process
14.7.8.3.1. Stable
transformation system
14.7.8.3.2. Transient
expression system
14.7.8.4. Rest
of Europe Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Application
14.7.8.4.1. Human
papillomavirus (HPV)
14.7.8.4.2. Hepatitis
B
14.7.8.4.3. Malaria
14.7.8.4.4. Norwalk
Virus
14.7.8.4.5. HIV
14.7.8.4.6. Ebola
Virus
14.7.8.4.7. SARS-CoV-2
Virus
14.7.8.4.8. Respiratory
Syncytial Virus (RSV)
14.7.8.4.9. Influenza
Virus
14.7.8.4.10. Others
14.7.8.5. Rest
of Europe Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By End Users
14.7.8.5.1. Research
Organizations
14.7.8.5.2. Biotechnology
Companies
14.7.8.5.3. Others
14.8. Key Segment for Channeling Investments
14.8.1. By
Country
14.8.2. By Type
14.8.3. By
Plant Type
14.8.4. By
Process
14.8.5. By
Application
14.8.6. By End
Users
15. Asia Pacific Plant-based Virus-Like Particles (VLP)
Technology Market Analysis and Forecasts, 2023 - 2031
15.1. Overview
15.1.1. Asia
Pacific Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn)
15.2. Asia Pacific Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Non-enveloped
Virus-Like Particles
15.2.2. Enveloped
Virus-Like Particles
15.2.3. Chimeric
Virus-Like Particles
15.3. Asia Pacific Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Plant Type
15.3.1. Nicotiana
benthamiana (tobacco)
15.3.2. Medicago
rativa (alfalfa)
15.3.3. Arabidopsis
thaliana (A. thaliana)
15.3.4. Potato
15.3.5. Oryza
sativa (Rice)
15.3.6. Lettuce
15.4. Asia Pacific Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Process
15.4.1. Stable
transformation system
15.4.2. Transient
expression system
15.5. Asia Pacific Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1. Human
papillomavirus (HPV)
15.5.2. Hepatitis
B
15.5.3. Malaria
15.5.4. Norwalk
Virus
15.5.5. HIV
15.5.6. Ebola
Virus
15.5.7. SARS-CoV-2
Virus
15.5.8. Respiratory
Syncytial Virus (RSV)
15.5.9. Influenza
Virus
15.5.10. Others
15.6. Asia Pacific Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.1. Research
Organizations
15.6.2. Biotechnology
Companies
15.6.3. Others
15.7. Asia Pacific Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1. China
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
15.7.1.1.1. Non-enveloped
Virus-Like Particles
15.7.1.1.2. Enveloped
Virus-Like Particles
15.7.1.1.3. Chimeric
Virus-Like Particles
15.7.1.2. China
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
15.7.1.2.1. Nicotiana
benthamiana (tobacco)
15.7.1.2.2. Medicago
rativa (alfalfa)
15.7.1.2.3. Arabidopsis
thaliana (A. thaliana)
15.7.1.2.4. Potato
15.7.1.2.5. Oryza
sativa (Rice)
15.7.1.2.6. Lettuce
15.7.1.3. China
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and Forecasts,
By Process
15.7.1.3.1. Stable
transformation system
15.7.1.3.2. Transient
expression system
15.7.1.4. China
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
15.7.1.4.1. Human
papillomavirus (HPV)
15.7.1.4.2. Hepatitis
B
15.7.1.4.3. Malaria
15.7.1.4.4. Norwalk
Virus
15.7.1.4.5. HIV
15.7.1.4.6. Ebola
Virus
15.7.1.4.7. SARS-CoV-2
Virus
15.7.1.4.8. Respiratory
Syncytial Virus (RSV)
15.7.1.4.9. Influenza
Virus
15.7.1.4.10. Others
15.7.1.5. China
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
15.7.1.5.1. Research
Organizations
15.7.1.5.2. Biotechnology
Companies
15.7.1.5.3. Others
15.7.2. Japan
15.7.2.1. Japan
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
15.7.2.1.1. Non-enveloped
Virus-Like Particles
15.7.2.1.2. Enveloped
Virus-Like Particles
15.7.2.1.3. Chimeric
Virus-Like Particles
15.7.2.2. Japan
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
15.7.2.2.1. Nicotiana
benthamiana (tobacco)
15.7.2.2.2. Medicago
rativa (alfalfa)
15.7.2.2.3. Arabidopsis
thaliana (A. thaliana)
15.7.2.2.4. Potato
15.7.2.2.5. Oryza
sativa (Rice)
15.7.2.2.6. Lettuce
15.7.2.3. Japan
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
15.7.2.3.1. Stable
transformation system
15.7.2.3.2. Transient
expression system
15.7.2.4. Japan
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
15.7.2.4.1. Human
papillomavirus (HPV)
15.7.2.4.2. Hepatitis
B
15.7.2.4.3. Malaria
15.7.2.4.4. Norwalk
Virus
15.7.2.4.5. HIV
15.7.2.4.6. Ebola
Virus
15.7.2.4.7. SARS-CoV-2
Virus
15.7.2.4.8. Respiratory
Syncytial Virus (RSV)
15.7.2.4.9. Influenza
Virus
15.7.2.4.10. Others
15.7.2.5. Japan
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
15.7.2.5.1. Research
Organizations
15.7.2.5.2. Biotechnology
Companies
15.7.2.5.3. Others
15.7.3. India
15.7.3.1. India
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
15.7.3.1.1. Non-enveloped
Virus-Like Particles
15.7.3.1.2. Enveloped
Virus-Like Particles
15.7.3.1.3. Chimeric
Virus-Like Particles
15.7.3.2. India
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
15.7.3.2.1. Nicotiana
benthamiana (tobacco)
15.7.3.2.2. Medicago
rativa (alfalfa)
15.7.3.2.3. Arabidopsis
thaliana (A. thaliana)
15.7.3.2.4. Potato
15.7.3.2.5. Oryza
sativa (Rice)
15.7.3.2.6. Lettuce
15.7.3.3. India
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
15.7.3.3.1. Stable
transformation system
15.7.3.3.2. Transient
expression system
15.7.3.4. India
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
15.7.3.4.1. Human
papillomavirus (HPV)
15.7.3.4.2. Hepatitis
B
15.7.3.4.3. Malaria
15.7.3.4.4. Norwalk
Virus
15.7.3.4.5. HIV
15.7.3.4.6. Ebola
Virus
15.7.3.4.7. SARS-CoV-2
Virus
15.7.3.4.8. Respiratory
Syncytial Virus (RSV)
15.7.3.4.9. Influenza
Virus
15.7.3.4.10. Others
15.7.3.5. India
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
15.7.3.5.1. Research
Organizations
15.7.3.5.2. Biotechnology
Companies
15.7.3.5.3. Others
15.7.4. New
Zealand
15.7.4.1. New
Zealand Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Type
15.7.4.1.1. Non-enveloped
Virus-Like Particles
15.7.4.1.2. Enveloped
Virus-Like Particles
15.7.4.1.3. Chimeric
Virus-Like Particles
15.7.4.2. New Zealand
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
15.7.4.2.1. Nicotiana
benthamiana (tobacco)
15.7.4.2.2. Medicago
rativa (alfalfa)
15.7.4.2.3. Arabidopsis
thaliana (A. thaliana)
15.7.4.2.4. Potato
15.7.4.2.5. Oryza
sativa (Rice)
15.7.4.2.6. Lettuce
15.7.4.3. New
Zealand Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Process
15.7.4.3.1. Stable
transformation system
15.7.4.3.2. Transient
expression system
15.7.4.4. New
Zealand Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Application
15.7.4.4.1. Human
papillomavirus (HPV)
15.7.4.4.2. Hepatitis
B
15.7.4.4.3. Malaria
15.7.4.4.4. Norwalk
Virus
15.7.4.4.5. HIV
15.7.4.4.6. Ebola
Virus
15.7.4.4.7. SARS-CoV-2
Virus
15.7.4.4.8. Respiratory
Syncytial Virus (RSV)
15.7.4.4.9. Influenza
Virus
15.7.4.4.10. Others
15.7.4.5. New
Zealand Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By End Users
15.7.4.5.1. Research
Organizations
15.7.4.5.2. Biotechnology
Companies
15.7.4.5.3. Others
15.7.5. Australia
15.7.5.1. Australia
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
15.7.5.1.1. Non-enveloped
Virus-Like Particles
15.7.5.1.2. Enveloped
Virus-Like Particles
15.7.5.1.3. Chimeric
Virus-Like Particles
15.7.5.2. Australia
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
15.7.5.2.1. Nicotiana
benthamiana (tobacco)
15.7.5.2.2. Medicago
rativa (alfalfa)
15.7.5.2.3. Arabidopsis
thaliana (A. thaliana)
15.7.5.2.4. Potato
15.7.5.2.5. Oryza
sativa (Rice)
15.7.5.2.6. Lettuce
15.7.5.3. Australia
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
15.7.5.3.1. Stable
transformation system
15.7.5.3.2. Transient
expression system
15.7.5.4. Australia
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
15.7.5.4.1. Human
papillomavirus (HPV)
15.7.5.4.2. Hepatitis
B
15.7.5.4.3. Malaria
15.7.5.4.4. Norwalk
Virus
15.7.5.4.5. HIV
15.7.5.4.6. Ebola
Virus
15.7.5.4.7. SARS-CoV-2
Virus
15.7.5.4.8. Respiratory
Syncytial Virus (RSV)
15.7.5.4.9. Influenza
Virus
15.7.5.4.10. Others
15.7.5.5. Australia
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
15.7.5.5.1. Research
Organizations
15.7.5.5.2. Biotechnology
Companies
15.7.5.5.3. Others
15.7.6. South
Korea
15.7.6.1. South
Korea Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Type
15.7.6.1.1. Non-enveloped
Virus-Like Particles
15.7.6.1.2. Enveloped
Virus-Like Particles
15.7.6.1.3. Chimeric
Virus-Like Particles
15.7.6.2. South
Korea Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Plant Type
15.7.6.2.1. Nicotiana
benthamiana (tobacco)
15.7.6.2.2. Medicago
rativa (alfalfa)
15.7.6.2.3. Arabidopsis
thaliana (A. thaliana)
15.7.6.2.4. Potato
15.7.6.2.5. Oryza
sativa (Rice)
15.7.6.2.6. Lettuce
15.7.6.3. South
Korea Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Process
15.7.6.3.1. Stable
transformation system
15.7.6.3.2. Transient
expression system
15.7.6.4. South
Korea Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Application
15.7.6.4.1. Human
papillomavirus (HPV)
15.7.6.4.2. Hepatitis
B
15.7.6.4.3. Malaria
15.7.6.4.4. Norwalk
Virus
15.7.6.4.5. HIV
15.7.6.4.6. Ebola
Virus
15.7.6.4.7. SARS-CoV-2
Virus
15.7.6.4.8. Respiratory
Syncytial Virus (RSV)
15.7.6.4.9. Influenza
Virus
15.7.6.4.10. Others
15.7.6.5. South
Korea Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By End Users
15.7.6.5.1. Research
Organizations
15.7.6.5.2. Biotechnology
Companies
15.7.6.5.3. Others
15.7.7. Southeast
Asia
15.7.7.1. Southeast
Asia Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Type
15.7.7.1.1. Non-enveloped
Virus-Like Particles
15.7.7.1.2. Enveloped
Virus-Like Particles
15.7.7.1.3. Chimeric
Virus-Like Particles
15.7.7.2. Southeast
Asia Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Plant Type
15.7.7.2.1. Nicotiana
benthamiana (tobacco)
15.7.7.2.2. Medicago
rativa (alfalfa)
15.7.7.2.3. Arabidopsis
thaliana (A. thaliana)
15.7.7.2.4. Potato
15.7.7.2.5. Oryza
sativa (Rice)
15.7.7.2.6. Lettuce
15.7.7.3. Southeast
Asia Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Process
15.7.7.3.1. Stable
transformation system
15.7.7.3.2. Transient
expression system
15.7.7.4. Southeast
Asia Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Application
15.7.7.4.1. Human
papillomavirus (HPV)
15.7.7.4.2. Hepatitis
B
15.7.7.4.3. Malaria
15.7.7.4.4. Norwalk
Virus
15.7.7.4.5. HIV
15.7.7.4.6. Ebola
Virus
15.7.7.4.7. SARS-CoV-2
Virus
15.7.7.4.8. Respiratory
Syncytial Virus (RSV)
15.7.7.4.9. Influenza
Virus
15.7.7.4.10. Others
15.7.7.5. Southeast
Asia Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By End Users
15.7.7.5.1. Research
Organizations
15.7.7.5.2. Biotechnology
Companies
15.7.7.5.3. Others
15.7.7.6. Southeast
Asia Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn)
and Forecasts, By Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest
of Southeast Asia
15.7.8. Rest of
Asia Pacific
15.7.8.1. Rest
of Asia Pacific Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By Type
15.7.8.1.1. Non-enveloped
Virus-Like Particles
15.7.8.1.2. Enveloped
Virus-Like Particles
15.7.8.1.3. Chimeric
Virus-Like Particles
15.7.8.2. Rest
of Asia Pacific Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By Plant Type
15.7.8.2.1. Nicotiana
benthamiana (tobacco)
15.7.8.2.2. Medicago
rativa (alfalfa)
15.7.8.2.3. Arabidopsis
thaliana (A. thaliana)
15.7.8.2.4. Potato
15.7.8.2.5. Oryza
sativa (Rice)
15.7.8.2.6. Lettuce
15.7.8.3. Rest
of Asia Pacific Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By Process
15.7.8.3.1. Stable
transformation system
15.7.8.3.2. Transient
expression system
15.7.8.4. Rest
of Asia Pacific Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.8.4.1. Human
papillomavirus (HPV)
15.7.8.4.2. Hepatitis
B
15.7.8.4.3. Malaria
15.7.8.4.4. Norwalk
Virus
15.7.8.4.5. HIV
15.7.8.4.6. Ebola
Virus
15.7.8.4.7. SARS-CoV-2
Virus
15.7.8.4.8. Respiratory
Syncytial Virus (RSV)
15.7.8.4.9. Influenza
Virus
15.7.8.4.10. Others
15.7.8.5. Rest
of Asia Pacific Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By End Users
15.7.8.5.1. Research
Organizations
15.7.8.5.2. Biotechnology
Companies
15.7.8.5.3. Others
15.8. Key Segment for Channeling Investments
15.8.1. By
Country
15.8.2. By Type
15.8.3. By
Plant Type
15.8.4. By
Process
15.8.5. By
Application
15.8.6. By End
Users
16. Middle East and Africa Plant-based Virus-Like Particles (VLP)
Technology Market Analysis and Forecasts, 2023 - 2031
16.1. Overview
16.1.1. Middle
East and Africa Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn)
16.2. Middle East and Africa Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Type
16.2.1. Non-enveloped
Virus-Like Particles
16.2.2. Enveloped
Virus-Like Particles
16.2.3. Chimeric
Virus-Like Particles
16.3. Middle East and Africa Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Plant Type
16.3.1. Nicotiana
benthamiana (tobacco)
16.3.2. Medicago
rativa (alfalfa)
16.3.3. Arabidopsis
thaliana (A. thaliana)
16.3.4. Potato
16.3.5. Oryza
sativa (Rice)
16.3.6. Lettuce
16.4. Middle East and Africa Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Process
16.4.1. Stable
transformation system
16.4.2. Transient
expression system
16.5. Middle East and Africa Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Application
16.5.1. Human
papillomavirus (HPV)
16.5.2. Hepatitis
B
16.5.3. Malaria
16.5.4. Norwalk
Virus
16.5.5. HIV
16.5.6. Ebola
Virus
16.5.7. SARS-CoV-2
Virus
16.5.8. Respiratory
Syncytial Virus (RSV)
16.5.9. Influenza
Virus
16.5.10. Others
16.6. Middle East and Africa Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.1. Research
Organizations
16.6.2. Biotechnology
Companies
16.6.3. Others
16.7. Middle East and Africa Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Country
16.7.1. Saudi
Arabia
16.7.1.1. Saudi
Arabia Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Type
16.7.1.1.1. Non-enveloped
Virus-Like Particles
16.7.1.1.2. Enveloped
Virus-Like Particles
16.7.1.1.3. Chimeric
Virus-Like Particles
16.7.1.2. Saudi
Arabia Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Plant Type
16.7.1.2.1. Nicotiana
benthamiana (tobacco)
16.7.1.2.2. Medicago
rativa (alfalfa)
16.7.1.2.3. Arabidopsis
thaliana (A. thaliana)
16.7.1.2.4. Potato
16.7.1.2.5. Oryza
sativa (Rice)
16.7.1.2.6. Lettuce
16.7.1.3. Saudi
Arabia Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Process
16.7.1.3.1. Stable
transformation system
16.7.1.3.2. Transient
expression system
16.7.1.4. Saudi
Arabia Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Application
16.7.1.4.1. Human
papillomavirus (HPV)
16.7.1.4.2. Hepatitis
B
16.7.1.4.3. Malaria
16.7.1.4.4. Norwalk
Virus
16.7.1.4.5. HIV
16.7.1.4.6. Ebola
Virus
16.7.1.4.7. SARS-CoV-2
Virus
16.7.1.4.8. Respiratory
Syncytial Virus (RSV)
16.7.1.4.9. Influenza
Virus
16.7.1.4.10. Others
16.7.1.5. Saudi
Arabia Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By End Users
16.7.1.5.1. Research
Organizations
16.7.1.5.2. Biotechnology
Companies
16.7.1.5.3. Others
16.7.2. UAE
16.7.2.1. UAE
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and Forecasts,
By Type
16.7.2.1.1. Non-enveloped
Virus-Like Particles
16.7.2.1.2. Enveloped
Virus-Like Particles
16.7.2.1.3. Chimeric
Virus-Like Particles
16.7.2.2. UAE
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
16.7.2.2.1. Nicotiana
benthamiana (tobacco)
16.7.2.2.2. Medicago
rativa (alfalfa)
16.7.2.2.3. Arabidopsis
thaliana (A. thaliana)
16.7.2.2.4. Potato
16.7.2.2.5. Oryza
sativa (Rice)
16.7.2.2.6. Lettuce
16.7.2.3. UAE
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
16.7.2.3.1. Stable
transformation system
16.7.2.3.2. Transient
expression system
16.7.2.4. UAE
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
16.7.2.4.1. Human
papillomavirus (HPV)
16.7.2.4.2. Hepatitis
B
16.7.2.4.3. Malaria
16.7.2.4.4. Norwalk
Virus
16.7.2.4.5. HIV
16.7.2.4.6. Ebola
Virus
16.7.2.4.7. SARS-CoV-2
Virus
16.7.2.4.8. Respiratory
Syncytial Virus (RSV)
16.7.2.4.9. Influenza
Virus
16.7.2.4.10. Others
16.7.2.5. UAE
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
16.7.2.5.1. Research
Organizations
16.7.2.5.2. Biotechnology
Companies
16.7.2.5.3. Others
16.7.3. Egypt
16.7.3.1. Egypt
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
16.7.3.1.1. Non-enveloped
Virus-Like Particles
16.7.3.1.2. Enveloped
Virus-Like Particles
16.7.3.1.3. Chimeric
Virus-Like Particles
16.7.3.2. Egypt
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
16.7.3.2.1. Nicotiana
benthamiana (tobacco)
16.7.3.2.2. Medicago
rativa (alfalfa)
16.7.3.2.3. Arabidopsis
thaliana (A. thaliana)
16.7.3.2.4. Potato
16.7.3.2.5. Oryza
sativa (Rice)
16.7.3.2.6. Lettuce
16.7.3.3. Egypt
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
16.7.3.3.1. Stable
transformation system
16.7.3.3.2. Transient
expression system
16.7.3.4. Egypt
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
16.7.3.4.1. Human
papillomavirus (HPV)
16.7.3.4.2. Hepatitis
B
16.7.3.4.3. Malaria
16.7.3.4.4. Norwalk
Virus
16.7.3.4.5. HIV
16.7.3.4.6. Ebola
Virus
16.7.3.4.7. SARS-CoV-2
Virus
16.7.3.4.8. Respiratory
Syncytial Virus (RSV)
16.7.3.4.9. Influenza
Virus
16.7.3.4.10. Others
16.7.3.5. Egypt
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
16.7.3.5.1. Research
Organizations
16.7.3.5.2. Biotechnology
Companies
16.7.3.5.3. Others
16.7.4. Kuwait
16.7.4.1. Kuwait
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
16.7.4.1.1. Non-enveloped
Virus-Like Particles
16.7.4.1.2. Enveloped
Virus-Like Particles
16.7.4.1.3. Chimeric
Virus-Like Particles
16.7.4.2. Kuwait
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
16.7.4.2.1. Nicotiana
benthamiana (tobacco)
16.7.4.2.2. Medicago
rativa (alfalfa)
16.7.4.2.3. Arabidopsis
thaliana (A. thaliana)
16.7.4.2.4. Potato
16.7.4.2.5. Oryza
sativa (Rice)
16.7.4.2.6. Lettuce
16.7.4.3. Kuwait
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
16.7.4.3.1. Stable
transformation system
16.7.4.3.2. Transient
expression system
16.7.4.4. Kuwait
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
16.7.4.4.1. Human
papillomavirus (HPV)
16.7.4.4.2. Hepatitis
B
16.7.4.4.3. Malaria
16.7.4.4.4. Norwalk
Virus
16.7.4.4.5. HIV
16.7.4.4.6. Ebola
Virus
16.7.4.4.7. SARS-CoV-2
Virus
16.7.4.4.8. Respiratory
Syncytial Virus (RSV)
16.7.4.4.9. Influenza
Virus
16.7.4.4.10. Others
16.7.4.5. Kuwait
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
16.7.4.5.1. Research
Organizations
16.7.4.5.2. Biotechnology
Companies
16.7.4.5.3. Others
16.7.5. South
Africa
16.7.5.1. South
Africa Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Type
16.7.5.1.1. Non-enveloped
Virus-Like Particles
16.7.5.1.2. Enveloped
Virus-Like Particles
16.7.5.1.3. Chimeric
Virus-Like Particles
16.7.5.2. South
Africa Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Plant Type
16.7.5.2.1. Nicotiana
benthamiana (tobacco)
16.7.5.2.2. Medicago
rativa (alfalfa)
16.7.5.2.3. Arabidopsis
thaliana (A. thaliana)
16.7.5.2.4. Potato
16.7.5.2.5. Oryza
sativa (Rice)
16.7.5.2.6. Lettuce
16.7.5.3. South
Africa Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Process
16.7.5.3.1. Stable
transformation system
16.7.5.3.2. Transient
expression system
16.7.5.4. South
Africa Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By Application
16.7.5.4.1. Human
papillomavirus (HPV)
16.7.5.4.2. Hepatitis
B
16.7.5.4.3. Malaria
16.7.5.4.4. Norwalk
Virus
16.7.5.4.5. HIV
16.7.5.4.6. Ebola
Virus
16.7.5.4.7. SARS-CoV-2
Virus
16.7.5.4.8. Respiratory
Syncytial Virus (RSV)
16.7.5.4.9. Influenza
Virus
16.7.5.4.10. Others
16.7.5.5. South
Africa Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn) and Forecasts, By End Users
16.7.5.5.1. Research
Organizations
16.7.5.5.2. Biotechnology
Companies
16.7.5.5.3. Others
16.7.6. Rest of
Middle East & Africa
16.7.6.1. Rest
of Middle East & Africa Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Type
16.7.6.1.1. Non-enveloped
Virus-Like Particles
16.7.6.1.2. Enveloped
Virus-Like Particles
16.7.6.1.3. Chimeric
Virus-Like Particles
16.7.6.2. Rest
of Middle East & Africa Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Plant Type
16.7.6.2.1. Nicotiana
benthamiana (tobacco)
16.7.6.2.2. Medicago
rativa (alfalfa)
16.7.6.2.3. Arabidopsis
thaliana (A. thaliana)
16.7.6.2.4. Potato
16.7.6.2.5. Oryza
sativa (Rice)
16.7.6.2.6. Lettuce
16.7.6.3. Rest
of Middle East & Africa Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Process
16.7.6.3.1. Stable
transformation system
16.7.6.3.2. Transient
expression system
16.7.6.4. Rest
of Middle East & Africa Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Application
16.7.6.4.1. Human
papillomavirus (HPV)
16.7.6.4.2. Hepatitis
B
16.7.6.4.3. Malaria
16.7.6.4.4. Norwalk
Virus
16.7.6.4.5. HIV
16.7.6.4.6. Ebola
Virus
16.7.6.4.7. SARS-CoV-2
Virus
16.7.6.4.8. Respiratory
Syncytial Virus (RSV)
16.7.6.4.9. Influenza
Virus
16.7.6.4.10. Others
16.7.6.5. Rest
of Middle East & Africa Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.6.5.1. Research
Organizations
16.7.6.5.2. Biotechnology
Companies
16.7.6.5.3. Others
16.8. Key Segment for Channeling Investments
16.8.1. By
Country
16.8.2. By Type
16.8.3. By
Plant Type
16.8.4. By Process
16.8.5. By
Application
16.8.6. By End
Users
17. Latin America Plant-based Virus-Like Particles (VLP)
Technology Market Analysis and Forecasts, 2023 - 2031
17.1. Overview
17.1.1. Latin
America Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$
Mn)
17.2. Latin America Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Type
17.2.1. Non-enveloped
Virus-Like Particles
17.2.2. Enveloped
Virus-Like Particles
17.2.3. Chimeric
Virus-Like Particles
17.3. Latin America Plant-based Virus-Like Particles (VLP) Technology
Market Revenue (US$ Mn) and Forecasts, By Plant Type
17.3.1. Nicotiana
benthamiana (tobacco)
17.3.2. Medicago
rativa (alfalfa)
17.3.3. Arabidopsis
thaliana (A. thaliana)
17.3.4. Potato
17.3.5. Oryza
sativa (Rice)
17.3.6. Lettuce
17.4. Latin America Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Process
17.4.1. Stable
transformation system
17.4.2. Transient
expression system
17.5. Latin America Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Application
17.5.1. Human
papillomavirus (HPV)
17.5.2. Hepatitis
B
17.5.3. Malaria
17.5.4. Norwalk
Virus
17.5.5. HIV
17.5.6. Ebola
Virus
17.5.7. SARS-CoV-2
Virus
17.5.8. Respiratory
Syncytial Virus (RSV)
17.5.9. Influenza
Virus
17.5.10. Others
17.6. Latin America Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By End Users
17.6.1. Research
Organizations
17.6.2. Biotechnology
Companies
17.6.3. Others
17.7. Latin America Plant-based Virus-Like Particles (VLP)
Technology Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1. Brazil
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and Forecasts,
By Type
17.7.1.1.1. Non-enveloped
Virus-Like Particles
17.7.1.1.2. Enveloped
Virus-Like Particles
17.7.1.1.3. Chimeric
Virus-Like Particles
17.7.1.2. Brazil
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
17.7.1.2.1. Nicotiana
benthamiana (tobacco)
17.7.1.2.2. Medicago
rativa (alfalfa)
17.7.1.2.3. Arabidopsis
thaliana (A. thaliana)
17.7.1.2.4. Potato
17.7.1.2.5. Oryza
sativa (Rice)
17.7.1.2.6. Lettuce
17.7.1.3. Brazil
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
17.7.1.3.1. Stable
transformation system
17.7.1.3.2. Transient
expression system
17.7.1.4. Brazil
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
17.7.1.4.1. Human
papillomavirus (HPV)
17.7.1.4.2. Hepatitis
B
17.7.1.4.3. Malaria
17.7.1.4.4. Norwalk
Virus
17.7.1.4.5. HIV
17.7.1.4.6. Ebola
Virus
17.7.1.4.7. SARS-CoV-2
Virus
17.7.1.4.8. Respiratory
Syncytial Virus (RSV)
17.7.1.4.9. Influenza
Virus
17.7.1.4.10. Others
17.7.1.5. Brazil
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
17.7.1.5.1. Research
Organizations
17.7.1.5.2. Biotechnology
Companies
17.7.1.5.3. Others
17.7.2. Argentina
17.7.2.1. Argentina
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Type
17.7.2.1.1. Non-enveloped
Virus-Like Particles
17.7.2.1.2. Enveloped
Virus-Like Particles
17.7.2.1.3. Chimeric
Virus-Like Particles
17.7.2.2. Argentina
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Plant Type
17.7.2.2.1. Nicotiana
benthamiana (tobacco)
17.7.2.2.2. Medicago
rativa (alfalfa)
17.7.2.2.3. Arabidopsis
thaliana (A. thaliana)
17.7.2.2.4. Potato
17.7.2.2.5. Oryza
sativa (Rice)
17.7.2.2.6. Lettuce
17.7.2.3. Argentina
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Process
17.7.2.3.1. Stable
transformation system
17.7.2.3.2. Transient
expression system
17.7.2.4. Argentina
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By Application
17.7.2.4.1. Human
papillomavirus (HPV)
17.7.2.4.2. Hepatitis
B
17.7.2.4.3. Malaria
17.7.2.4.4. Norwalk
Virus
17.7.2.4.5. HIV
17.7.2.4.6. Ebola
Virus
17.7.2.4.7. SARS-CoV-2
Virus
17.7.2.4.8. Respiratory
Syncytial Virus (RSV)
17.7.2.4.9. Influenza
Virus
17.7.2.4.10. Others
17.7.2.5. Argentina
Plant-based Virus-Like Particles (VLP) Technology Market Revenue (US$ Mn) and
Forecasts, By End Users
17.7.2.5.1. Research
Organizations
17.7.2.5.2. Biotechnology
Companies
17.7.2.5.3. Others
17.7.3. Rest of
Latin America
17.7.3.1. Rest
of Latin America Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By Type
17.7.3.1.1. Non-enveloped
Virus-Like Particles
17.7.3.1.2. Enveloped
Virus-Like Particles
17.7.3.1.3. Chimeric
Virus-Like Particles
17.7.3.2. Rest
of Latin America Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By Plant Type
17.7.3.2.1. Nicotiana
benthamiana (tobacco)
17.7.3.2.2. Medicago
rativa (alfalfa)
17.7.3.2.3. Arabidopsis
thaliana (A. thaliana)
17.7.3.2.4. Potato
17.7.3.2.5. Oryza
sativa (Rice)
17.7.3.2.6. Lettuce
17.7.3.3. Rest
of Latin America Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By Process
17.7.3.3.1. Stable
transformation system
17.7.3.3.2. Transient
expression system
17.7.3.4. Rest
of Latin America Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By Application
17.7.3.4.1. Human
papillomavirus (HPV)
17.7.3.4.2. Hepatitis
B
17.7.3.4.3. Malaria
17.7.3.4.4. Norwalk
Virus
17.7.3.4.5. HIV
17.7.3.4.6. Ebola
Virus
17.7.3.4.7. SARS-CoV-2
Virus
17.7.3.4.8. Respiratory
Syncytial Virus (RSV)
17.7.3.4.9. Influenza
Virus
17.7.3.4.10. Others
17.7.3.5. Rest
of Latin America Plant-based Virus-Like Particles (VLP) Technology Market
Revenue (US$ Mn) and Forecasts, By End Users
17.7.3.5.1. Research
Organizations
17.7.3.5.2. Biotechnology
Companies
17.7.3.5.3. Others
17.8. Key Segment for Channeling Investments
17.8.1. By
Country
17.8.2. By Type
17.8.3. By
Plant Type
17.8.4. By
Process
17.8.5. By
Application
17.8.6. By End
Users
18. Competitive Benchmarking
18.1. Global Presence and Growth Strategies
18.1.1. Mergers
and Acquisitions
18.1.2. Product
Launches
18.1.3. Investments
Trends
18.1.4. R&D
Initiatives
19. Player Profiles
19.1. Creative Biolabs
19.1.1. Company
Details
19.1.2. Company
Overview
19.1.3. Product
Offerings
19.1.4. Key
Developments
19.1.5. Financial
Analysis
19.1.6. SWOT
Analysis
19.1.7. Business
Strategies
19.2. Creative
Biostructure
19.2.1. Company
Details
19.2.2. Company
Overview
19.2.3. Product
Offerings
19.2.4. Key
Developments
19.2.5. Financial
Analysis
19.2.6. SWOT
Analysis
19.2.7. Business
Strategies
19.3. Icon Genetics
GmbH
19.3.1. Company
Details
19.3.2. Company
Overview
19.3.3. Product
Offerings
19.3.4. Key
Developments
19.3.5. Financial
Analysis
19.3.6. SWOT Analysis
19.3.7. Business
Strategies
19.4. Leaf Expression
Systems
19.4.1. Company
Details
19.4.2. Company
Overview
19.4.3. Product
Offerings
19.4.4. Key
Developments
19.4.5. Financial
Analysis
19.4.6. SWOT
Analysis
19.4.7. Business
Strategies
19.5. Medicago Inc.
19.5.1. Company
Details
19.5.2. Company
Overview
19.5.3. Product
Offerings
19.5.4. Key Developments
19.5.5. Financial
Analysis
19.5.6. SWOT
Analysis
19.5.7. Business
Strategies
19.6. Wuhan Healthgen
Biotechnology Corp
19.6.1. Company
Details
19.6.2. Company
Overview
19.6.3. Product
Offerings
19.6.4. Key
Developments
19.6.5. Financial
Analysis
19.6.6. SWOT
Analysis
19.6.7. Business
Strategies
19.7. Other Market Participants
20. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive
for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.